SLC6A11 Antibody

What is SLC6A11 and why is it significant in neurological research?

SLC6A11 (Solute Carrier Family 6 Member 11) encodes the sodium- and chloride-dependent GABA transporter 3 (GAT-3), which plays a crucial role in regulating inhibitory neurotransmission in the brain. It functions by uptaking gamma-aminobutyric acid (GABA) from the synaptic cleft, effectively terminating GABA neurotransmission. This protein is particularly significant in neurological research as defects in the SLC6A11 gene have been associated with epilepsy, behavioral abnormalities, and intellectual problems . Recent studies have also implicated SLC6A11 in circadian rhythm regulation through interactions with Rev-erbα, suggesting its broader involvement in neurophysiological processes beyond simple GABA clearance .

How do I select the appropriate SLC6A11 antibody for my specific experimental applications?

When selecting an SLC6A11 antibody, consider these critical factors:

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IHC, ICC, IP, ELISA, etc.)

• Species reactivity: Confirm cross-reactivity with your experimental model (human, mouse, rat)

• Epitope location: Different antibodies recognize different regions of SLC6A11 (N-terminal, internal region, C-terminal)

• Clonality: Polyclonal antibodies offer broader epitope recognition while monoclonal antibodies provide higher specificity

• Validation data: Review published literature and validation data from manufacturers

For example, antibody 13920-1-AP has been validated for WB, IHC, and ELISA applications with human and mouse samples, while ABIN2690507 has been validated for WB, IHC, ICC, and IP with rat and mouse samples .

What are the predicted versus observed molecular weights for SLC6A11 in Western blot applications?

According to the search results, there are discrepancies between calculated and observed molecular weights for SLC6A11:

The mobility discrepancy is likely due to post-translational modifications, protein degradation, or alternative splicing. Western blotting detects proteins based on antigen-antibody binding, and the mobility rate can be influenced by multiple factors . For accurate interpretation, always run appropriate positive controls alongside your samples.

What are the recommended protocols for SLC6A11 antibody applications in Western blotting?

For optimal Western blot results with SLC6A11 antibodies:

• Sample preparation:

  • Brain tissue samples (particularly cerebellum) yield the strongest signals

  • Use RIPA buffer with protease inhibitors for protein extraction

• Recommended dilutions:

  • Proteintech 13920-1-AP: 1:500-1:1000

  • Elabscience E-AB-17981: 1:500-1:2000

• Detection system:

  • HRP-conjugated secondary antibodies work well with standard ECL detection

  • Expected band size: 65-70 kDa (though actual band size may vary)

• Positive controls:

  • Mouse cerebellum tissue lysate is recommended as a positive control

  • Rat brain tissue has been verified for several antibodies

Always start with the recommended dilution and optimize based on your specific experimental conditions and detection system.

How should I optimize immunohistochemistry protocols for SLC6A11 detection in brain tissues?

For optimal immunohistochemistry results with SLC6A11 antibodies:

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

• Antibody dilutions:

  • Proteintech 13920-1-AP: 1:200-1:800

  • For other antibodies, begin with manufacturer recommendations and titrate

• Incubation conditions:

  • Overnight incubation at 4°C typically yields optimal results

  • Use a blocking solution containing 5% normal serum from the species of the secondary antibody

• Detection systems:

  • DAB-based chromogenic detection works well for standard brightfield microscopy

  • For fluorescence, Alexa Fluor or similar fluorophore-conjugated secondary antibodies are recommended

• Controls:

  • Mouse brain tissue serves as a positive control

  • Always include a negative control (primary antibody omission)

What approaches should be considered when studying SLC6A11 variants or mutations?

When investigating SLC6A11 variants or mutations:

• Functional characterization approaches:

  • Radioactive 3H γ-aminobutyric acid uptake assays in cells and synaptosomes

  • Brain slice surface protein biotinylation

  • Immunohistochemistry with confocal microscopy

• Model systems:

  • Cell models: Neuro-2a cells, primary hippocampal neurons, primary cortex neurons

  • Animal models: Slc6a1+/A288V and Slc6a1+/S295L mice represent partial or complete loss of function

• Specific inhibitors:

  • Use GAT-specific inhibitors like NO-711 and SNAP-5114 to validate functional effects

• Analysis parameters:

  • Protein trafficking and stability

  • GABA uptake capacity

  • Compensatory changes in GABA receptor expression

Research has shown that SLC6A1/SLC6A11 mutations often lead to impaired protein trafficking resulting in partial or complete loss of γ-aminobutyric acid uptake, which may be the primary disease mechanism .

How should SLC6A11 antibodies be stored and handled to maintain optimal performance?

For optimal antibody performance:

• Storage conditions:

  • Store at -20°C in small aliquots to avoid freeze-thaw cycles

  • Most antibodies are stable for 12 months after shipment when properly stored

• Shipping and receipt:

  • Products are typically shipped with ice packs

  • Upon receipt, immediately store at the recommended temperature

• Buffer composition:

  • Most SLC6A11 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3-7.4

  • Some may contain stabilizers (e.g., 0.05% stabilizer)

• Handling precautions:

  • Avoid repeated freeze-thaw cycles

  • For some formulations (e.g., 20μL sizes), aliquoting is unnecessary for -20°C storage

  • Some preparations may contain 0.1% BSA or other stabilizers

What controls should be included when validating SLC6A11 antibody specificity in experimental systems?

To ensure antibody specificity:

• Positive controls:

  • Tissue-specific: Mouse cerebellum and rat brain tissues are verified positive controls

  • Recombinant protein: Purified SLC6A11 protein or overexpression systems

• Negative controls:

  • Primary antibody omission

  • Blocking peptide competition assay

  • siRNA/shRNA knockdown samples

  • SLC6A11 knockout tissues (if available)

• Cross-reactivity assessment:

  • Test in tissues from different species if working with non-validated species

  • Consider testing in tissues with known low/no expression

• Application-specific controls:

  • For IHC: Include isotype controls

  • For WB: Include molecular weight markers and verify band size (65-70 kDa range)

  • For immunoprecipitation: Include IgG control

How do post-translational modifications affect SLC6A11 detection and antibody selection?

Post-translational modifications significantly impact SLC6A11 detection:

• Impact on molecular weight:

  • Observed MW (65-70 kDa) often differs from calculated MW (71 kDa)

  • Multiple bands may appear due to different modified forms simultaneously present in samples

• Epitope masking:

  • Phosphorylation, glycosylation, or other modifications may mask antibody epitopes

  • Consider using antibodies targeting different regions of the protein

• Membrane localization:

  • SLC6A11 is primarily localized to the membrane

  • Trafficking-deficient variants may show altered subcellular localization

  • Consider membrane fractionation techniques for enrichment

• Antibody selection strategies:

  • Use antibodies targeting conserved regions less likely to be modified

  • For studying specific modifications, use modification-specific antibodies

How can SLC6A11 antibodies be used to investigate the relationship between GABA transport and neurological disorders?

SLC6A11 antibodies can be employed in several advanced applications:

• Comparative expression studies:

  • Compare SLC6A11 expression levels in brain tissues from epilepsy models versus controls

  • Investigate expression changes in different brain regions in neurodevelopmental disorders

• Functional studies:

  • Combine with electrophysiology to correlate SLC6A11 expression with GABAergic signaling

  • Use in conjunction with GABA uptake assays to correlate protein levels with function

• Regulatory network analysis:

  • Investigate Rev-erbα regulation of SLC6A11 expression in circadian rhythm disorders

  • Examine transcriptional and post-transcriptional regulation mechanisms

• Therapeutic target validation:

  • Evaluate changes in SLC6A11 expression/localization following treatment with potential therapeutics

  • Monitor compensatory changes in GABAergic signaling components

Research has demonstrated that dysregulation of SLC6A11 by Rev-erbα can impair GABAergic function, potentially contributing to epileptic phenotypes by altering GABA clearance from the synapse .

What approaches can be used to simultaneously investigate multiple components of GABAergic signaling including SLC6A11?

For comprehensive GABAergic system analysis:

• Multiplex immunofluorescence:

  • Simultaneously detect SLC6A11 with GABA receptors, other transporters, or synthesizing enzymes

  • Use spectrally distinct fluorophores and confocal microscopy

• Sequential immunoprecipitation:

  • Isolate protein complexes containing multiple GABAergic components

  • Identify interaction partners through mass spectrometry

• Functional correlation:

  • Combine radioactive 3H γ-aminobutyric acid uptake with electrophysiology

  • Use specific inhibitors (NO-711, SNAP-5114) to dissect contributions of different transporters

• Transcriptional profiling:

  • Analyze co-expression patterns of SLC6A11 with other GABAergic components

  • Investigate common regulatory mechanisms

Research has shown that when studying SLC6A mutations, it's valuable to assess compensatory changes in GABA receptors, which can modify disease pathophysiology and phenotype .

How can SLC6A11 antibodies be utilized in studies exploring the role of astrocytic GABA transport in neuroinflammation?

For investigating SLC6A11 in neuroinflammation contexts:

• Cell-type specific localization:

  • Use double-labeling with astrocytic markers (GFAP, S100β) and SLC6A11

  • Quantify changes in astrocytic SLC6A11 expression during inflammatory states

• Functional assessment:

  • Measure GABA uptake capacity in isolated astrocytes under inflammatory conditions

  • Correlate with SLC6A11 protein levels detected by antibodies

• Inflammatory mediator effects:

  • Treat primary cultures with cytokines/inflammatory mediators and assess SLC6A11 regulation

  • Investigate signaling pathways involved using pharmacological inhibitors

• In vivo inflammation models:

  • Use LPS-induced or disease-specific neuroinflammation models

  • Perform temporal analysis of SLC6A11 expression changes

Recent research has identified interactions between neurons, endothelial cells, and astrocytes that cooperatively regulate the astrocytic transcriptome, potentially including SLC6A11, which could be critical during neuroinflammatory states .

What are common issues when working with SLC6A11 antibodies and how can they be resolved?

Common challenges and solutions:

• Multiple bands in Western blot:

  • Expected issue due to different modified forms of SLC6A11

  • Solution: Use positive controls to identify the correct band; consider membrane fractionation

• Weak or no signal:

  • Increase antibody concentration; extend incubation time

  • Use more sensitive detection systems

  • Verify sample preparation (brain tissue, particularly cerebellum, yields stronger signals)

• High background:

  • Increase blocking time/concentration

  • Optimize washing steps (more frequent/longer washes)

  • Reduce primary and secondary antibody concentrations

• Non-specific binding:

  • Pre-absorb primary antibody with non-specific proteins

  • Use more stringent washing conditions

  • Validate with knockout/knockdown controls

• Inconsistent results:

  • Standardize tissue collection, fixation, and processing

  • Use the same lot of antibody when possible

  • Maintain consistent experimental conditions

How should researchers approach contradictory results when analyzing SLC6A11 expression across different experimental techniques?

When facing contradictory results:

• Technical validation:

  • Verify antibody specificity with appropriate controls

  • Confirm that the antibody recognizes the same epitope across techniques

  • Consider using multiple antibodies targeting different regions

• Sample preparation considerations:

  • Different fixation methods may affect epitope accessibility

  • Protein denaturation in WB versus native conformation in IHC can yield different results

  • Membrane protein extraction efficiency varies between protocols

• Resolution strategies:

  • Combine protein-level detection (antibodies) with mRNA analysis

  • Use functional assays (GABA uptake) to correlate with expression data

  • Employ genetic models (knockdown/knockout) for validation

• Interpretation approach:

  • Consider biological context (brain region, developmental stage, pathological condition)

  • Account for post-translational modifications and protein trafficking

  • Document experimental conditions thoroughly for reproducibility

What strategies can improve detection sensitivity when studying SLC6A11 in tissues with low expression levels?

For enhancing detection of low-abundance SLC6A11:

• Signal amplification methods:

  • Tyramide signal amplification for immunohistochemistry

  • Enhanced chemiluminescence systems for Western blot

  • Biotin-streptavidin amplification systems

• Sample enrichment:

  • Membrane fractionation to concentrate SLC6A11

  • Immunoprecipitation before Western blotting

  • Laser capture microdissection for region-specific analysis

• Detection system optimization:

  • Use high-sensitivity digital imaging systems

  • Increase exposure time (within linear range)

  • Consider fluorescent secondary antibodies with low background

• Protocol modifications:

  • Extended primary antibody incubation (overnight at 4°C)

  • Reduced washing stringency (shorter/fewer washes)

  • Optimized antigen retrieval methods for immunohistochemistry

How should researchers interpret differences in SLC6A11 subcellular localization between normal and pathological states?

For analyzing subcellular localization changes:

• Quantitative approaches:

  • Measure membrane-to-cytoplasmic ratio using image analysis

  • Perform subcellular fractionation followed by Western blotting

  • Use super-resolution microscopy for detailed localization

• Co-localization analysis:

  • Evaluate co-localization with membrane markers versus intracellular compartment markers

  • Calculate Pearson's or Mander's coefficients for quantitative comparison

• Trafficking assessment:

  • Investigate co-localization with endosomal/lysosomal markers to assess degradation

  • Use protein trafficking inhibitors to determine if mislocalization is dynamic or static

• Functional correlation:

  • Correlate subcellular localization changes with GABA uptake capacity

  • Investigate compensatory mechanisms (e.g., changes in other transporters or receptors)

Changes in SLC6A11 localization often indicate trafficking defects, which research has shown to be a common mechanism in pathological SLC6A11 variants associated with epilepsy and other neurological disorders .

What are the implications of diurnal rhythm variations in SLC6A11 expression for experimental design and data interpretation?

Considering diurnal variations:

• Experimental design considerations:

  • Standardize tissue collection time across experimental groups

  • Document time of sample collection in relation to light/dark cycle

  • Consider temporal sampling at multiple timepoints for complete characterization

• Data interpretation factors:

  • Compare results only between samples collected at the same circadian timepoint

  • Consider diurnal rhythm phase shifts in disease models

  • Evaluate expression in context of regulatory factors like Rev-erbα

• Rhythm analysis approaches:

  • Use cosinor analysis to quantify rhythm parameters

  • Perform time-series sampling for complete circadian profiling

  • Correlate with behavioral or physiological rhythms

Research has demonstrated that SLC6A11 expression shows diurnal rhythms that can be blunted in Rev-erbα knockout mice, indicating circadian regulation of this GABA transporter . This has important implications for timing-dependent efficacy of GABAergic drugs and interpretation of experimental results.

How can researchers effectively correlate SLC6A11 expression data with functional GABA transport metrics?

For correlating expression with function: